EW
Edwards Lifesciences CorporationEvidence as of 2026-10-14The desk's Snapshot
3 of 15 open to everyone · members see allRead the full desk report on EW
Seven analysts, the debate, the risk review, every claim cited. And the same for every name you hold.
Free plan, no credit card required. Silver opens the full report, $19.99 a month. AI-written · every claim cites a source · Insight, not advice.
Overview · Edwards Lifesciences Corporation
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. T…
Management team
- Mr. Daveen Chopra · Corporate Vice President of Transcatheter Mitral & Tricuspid TherapiesFind on LinkedIn
- Mr. Jean-Luc Lemercier · Corporate Vice President of Japan, Asia Pacific & Greater ChinaFind on LinkedIn
- Mr. Larry L. Wood · Corporate VP and Group President of TAVR & Surgical Structural HeartFind on LinkedIn
- Mr. Donald E. Bobo Jr. · Corporate Vice President of Strategy & Corporate DevelopmentFind on LinkedIn
Start free to see the full management team.
Links open LinkedIn searches, not verified profiles. Team data from our market-data vendor's company profile.
Moneyta sentiment
Where the published evidence leans after the desk debated it, not a rating or a recommendation.
−0.4 on a −2 to +2 scale.
What builds the score
Solid bars are analyst rubric scores; faded bars are computed directly from data. Claims dropped in debate count for nothing; weakened claims count at half weight.
Editor's note
Written after the debate settled. The rest of the page is the evidence behind it.
The evidence balance is Mixed ( -0.4 of a possible +2; confidence high). Revenue rose across the reported quarters from $ 1,553,100,000 in fiscal Q3 2025 (fiscal quarter ended 2025-10-31) to $ 1,648,600,000 in fiscal Q1 2026 (fiscal quarter ended 2026-04-30) and $ 1,741,000,000 in fiscal Q2 2026 (fiscal quarter ended 2026-07-31). Gross profit held near the high 70s as a percentage of sales (~ 77.8% in fiscal Q3 2025, ~ 78.0% in fiscal Q1 2026 and ~ 77.5% in fiscal Q2 2026) while operating income expanded from $ 307,100,000 in fiscal Q3 2025 to $ 513,200,000 in fiscal Q2 2026.
Net income and diluted EPS increased from $ 291,100,000 and $ 0.50 in fiscal Q3 2025 to $ 380,700,000 and $ 0.66 in fiscal Q1 2026, then fell to $ 241,900,000 and $ 0.42 in fiscal Q2 2026. Shares outstanding ran lower over the period (weighted‑average diluted shares of 585,700,000 in fiscal Q3 2025, 580,700,000 in fiscal Q1 2026 and 577,600,000 in fiscal Q2 2026) and the company recorded $ 421,800,000 of common‑stock repurchases in fiscal Q1 2026. Cash and cash equivalents were roughly in the $ 2.4–2.9 billion range across reported dates, long‑term debt noncurrent stayed near $ 598,200,000–$ 598,700,000, and trailing multiples show a P/E of 39.85, EV/EBITDA of 25.18 and P/FCF of 146.1 on trailing twelve‑month figures.
How this note was made
every stage ran before the note was writtenAnalyst desk
Mercer, Oakes, Nash, Ellis, Yates, Talbot and Archer. The desk: named AI agents, not people. Each reads one slice of the evidence and nothing else (no outside knowledge, no browsing), so every finding traces to a source you can open.
Reads the XBRL figures companies file with the SEC (revenue, margins, income, debt and share count, quarter by quarter) and reports which way the trend is running.
Revenue was $1,553,100,000 in fiscal Q3 2025 (2025-07-01 to 2025-09-30, 3mo), $1,648,600,000 in fiscal Q1 2026 (2026-01-01 to 2026-03-31, 3mo) and $1,741,000,000 in fiscal Q2 2026 (2026-04-01 to 2026-06-30, 3mo).
XBRL companyfacts · 0001099800-25-000062Gross profit was $1,207,900,000 in fiscal Q3 2025, $1,286,000,000 in fiscal Q1 2026 and $1,348,600,000 in fiscal Q2 2026, implying gross margin percentages of ~77.8% (Q3 2025), ~78.0% (Q1 2026) and ~77.5% (Q2 2026) when compared to the revenues reported for those quarters.
XBRL companyfacts · 0001099800-25-000062Reads the filings themselves, above all the year-over-year diff of Item 1A risk factors: which risks a company added, dropped or quietly reworded since its last annual report.
Which filings the desk reads
The desk reads the annual 10-K in full: its risk factors, and how they changed since last year. Quarterly 10-Qs and event filings (8-Ks, insider Form 4s) are listed for context but not read line by line: the 10-K is where the material risk disclosures live. A brand-new company, or one we have only just begun tracking, may have no annual report on file yet; its risk analysis fills in once that lands.
In the Form 10-K filed 25 February 2026, the company added a risk item stating that its use of, or failure to timely utilize, emerging technologies including AI could adversely impact the business and that the legal and regulatory landscape surrounding AI is rapidly evolving and uncertain.
Item 1A risk-factor diff · 0001099800-26-000009 vs 0001099800-25-000005In the Form 10-K filed 25 February 2026, the company added explicit pandemic/public-health language that frames public health crises (including pandemics and epidemics) as risks that could disrupt the business, hospital systems and supply chains and result in material adverse impacts.
Item 1A risk-factor diff · 0001099800-26-000009 vs 0001099800-25-000005Reads the signal panel above (momentum, volatility, drawdown, relative strength and beta) and ranks each against the whole research universe rather than judging it in isolation.
Momentum over the past 6 months is +9.0% and ranks in the 64th percentile of the 881-stock research universe on 2026-10-13.
Moneyta signal set · 2026-10-13weakened in debateMomentum using the 12_1 measure is +9.6% and ranks in the 51th percentile of the 881-stock research universe on 2026-10-13.
Moneyta signal set · 2026-10-13weakened in debateReads which funds hold the name and at what weight, plus insider Form 4 filings, to show the exposure you may already carry through index funds.
The reported 13F aggregate institutional holdings value was "$46.54B" as of the filing period ended 2026-06-30.
13F holdings · 1342 filers · as of 2026-06-30Top institutional holders reported include BlackRock, Inc. at "$5.32B", VANGUARD CAPITAL MANAGEMENT LLC at "$3.40B", VANGUARD PORTFOLIO MANAGEMENT LLC at "$2.39B", STATE STREET CORP at "$2.38B", and JPMORGAN CHASE & CO at "$2.08B" in the 13F for the period ended 2026-06-30.
13F holdings · 1342 filers · as of 2026-06-30Reads recent headlines that are genuinely about this company, ignoring rating chatter and market-wide stories. Findings argue in the debate but never move the sentiment score.
Multiple headlines note an FDA approval of the AUTUS Size-Adjustable Valve for pediatric pulmonary valve replacement and discuss renewed investor attention following that approval (article published 12 October 2026).
News · simplywall.st · 2026-10-12Press coverage announces Edwards Lifesciences will report operating results for the quarter ended 30 September 2026 after the market closes on 4 November 2026 and will host a conference call that day (article published 7 October 2026).
News · finance.yahoo.com · 2026-10-07Reads parsed Forms 3/4/5: who bought or sold, at what size, and whether a 10b5-1 plan was involved. Flags clustered open-market officer buying; treats plan sales as routine and never counts a fund or 10%-holder as an officer.
On 2026-08-26 Daveen Chopra (CVP, TMTT, Surgical & IHFM) reported multiple transactions including an entry listing "$2.3M" for 31800 shares (action code M) and separate sales of "$106k" (1154 shares) and "$2.8M" (30646 shares) in filings.
Form 4 · Chopra Daveen (CVP, TMTT, Surgical & IHFM) · $2.3M code M · 2026-08-26Daniel J. Lippis (CVP, TAVR) has multiple transactions filed as part of a 10b5-1 plan (stated on the filings), including entries on 2026-08-11 and 2026-09-11 each listing 619 shares and values of "$57k" and "$54k" (sold) and code M entries for "$45k" and "$45k".
Form 4 · Lippis Daniel J. (CVP, TAVR) · $45k code M · 2026-08-11Reads the implied-expectations math built from the company's own filings (the growth rate today's price would justify, and the multiples beside it) and argues whether the market's bar looks high or low for this business. Never turns the math into a target.
The valuation model reports an implied free cash flow (FCF) growth rate of 66.54% per year that the current price would justify under the stated discount and terminal assumptions.
Valuation inputs · SEC XBRL + stored EOD closePrice-to-free-cash-flow (P/FCF) on trailing twelve months FCF is 146.1.
Valuation inputs · SEC XBRL + stored EOD closeDebate and risk review
A bull and a bear contest the claims and the chair rules on each; the risk review stress-tests what survived.
A bull and a bear argue the analysts' claims across two rounds, then a chair rules on each one. Only what survives feeds the score. The argument is shown, not hidden, so you can judge the reasoning yourself.
Several claims together support a favorable read: sequential revenue increases (fundamentals-0) accompanied by operating income expansion (fundamentals-2) indicate improving core profitability, while ongoing share count reduction and a material repurchase program (fundamentals-4, fundamentals-5) bolster per‑share economics. Market signals show positive momentum, a golden‑cross technical setup, and below‑market beta (market-0, market-2, market-4), and large institutional holdings (ownership-0, ownership-1) align with continued investor interest. These items jointly counterbalance isolated negative datapoints by emphasizing improving operating performance, active capital returns, and persistent institutional participation.
Chair's verdict, claim by claim
Fragility · computed, not argued
balanced0.32
37 surviving claims rest on 18 distinct sources; the heaviest analyst carries 19% of them, and 97% of what the desk raised survived the debate.
The evidence set rests on a moderate number of distinct sources but a relatively small analyst concentration and very high claim survivorship — that pattern raises two points. First, surviving claims appear internally consistent and were rarely overturned in debate, which supports treating them as a coherent read of the public record; second, because many claims derive from a limited set of filings and a handful of analysts, the read is sensitive to new filings or additional independent sources and should be weighted accordingly.
Peer context · computed, not argued
12-1 momentum ranks 3rd of 8 in Medical Devices (as of 2026-10-13).
90-day volatility ranks 7th of 8 in Medical Devices (as of 2026-10-13).
Disconfirming evidence · base rates · falsifiers
Context
Outside consensus, and where this name already sits in your own portfolio.
Third-party consensus shown for context. It never enters Moneyta sentiment. When the two diverge, the debate above is where the why lives.
What this was built from
Every figure on this page traces to one of these. The desk reads only what is listed here (no outside knowledge, no browsing), and each card shows who read it and what it contributed to the score.
10 filings· 2 cited
SEC XBRL filings
Quarterly figures as filed with the SEC, read straight from EDGAR's structured data, not retyped or estimated.
Read by Mercer+0.4 to the score
13 documents· 2 cited
SEC filing documents
The filings themselves, including the year-over-year comparison of Item 1A risk factors.
Read by Oakes−0.8 to the score
1 signal set
Moneyta signal set
Computed from our own end-of-day price history and ranked against the whole research universe. No AI involved.
Read by Nash+0.3 to the score
3 holdings records· 1 cited
Fund holdings
Which funds hold this name and at what weight, plus insider Form 4 filings.
Read by Ellis+0.6 to the score
8 headlines· 2 cited
News coverage
Recent headlines about this company, rating chatter excluded and nothing published after the report date.
Read by Yatesnothing survived
12 filings· 2 cited
Insider filings
Parsed Forms 3/4/5 from EDGAR: named insiders, share counts, prices, and 10b5-1 plan state, with stated and inferred flags kept apart.
Read by Talbot−0.8 to the score
1 computation
Valuation inputs
TTM cash-flow figures from the company's own XBRL filings, priced with the stored closing price. Implied growth and multiples only; no fair-value dollar figure reaches the desk, by design.
Read by Archercontext only
1 record· 0 cited
Company profile
Sector, industry and company details.
1 record· 0 cited
Analyst consensus
Third-party consensus, shown for context only; it never enters Moneyta sentiment.
Read means we pulled and handed it to an analyst; cited means a claim on this page points at it. Reading twelve quarters to state one trend is normal; the gap is shown rather than hidden.
Written by AI, checked against sources
The analysts, the bull–bear debate and the editor's note are AI agents reading only the evidence listed on this page. They can misread a filing or a headline, which is why every claim cites a source you can open and check yourself. The sentiment score is arithmetic over the claims that survived the debate, not a language model's opinion.
Educational analysis of published data. Moneyta does not give investment advice or make recommendations. Past patterns do not indicate future results.
The full terminal on EW Gold
Who holds it, who's buying, what the Street thinks: live behind the lock, updated as filings land.
Institutional holders
Net institutional flow, Q/Q
Largest holder position
Insider buys, 90 days
Clustered insider value
Street target range
The real figures are for members. Educational analysis, not advice.
Get this for the names you actually hold
Every name in your portfolio, researched the same way, plus the one thing no sample can show: how each one sits inside what you already own.
Educational analysis of published data. Moneyta does not give investment advice or make recommendations.